Published January 1, 2020
| Version v1
Journal article
Open
The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients
Creators
- 1. Istanbul Univ, Aziz Sancar Inst Expt Med, Dept Neurosci, Istanbul, Turkey
- 2. Istanbul Univ, Istanbul Med Fac, Dept Neurol, Istanbul, Turkey
- 3. Bakirkoy Res & Training Hosp Psychiat & Neurol Di, Dept Neurol, Istanbul, Turkey
- 4. Demiroglu Bilim Univ, Sisli Florence Nightingale Hosp, Dept Neurol, Istanbul, Turkey
- 5. Istanbul Univ, Dept Physiol, Istanbul, Turkey
Description
B cells play a major role in the pathophysiology of myasthenia gravis (MG) with their ability to produce disease specific, pathogenic antibodies. However, their status during disease development and follow-up stages of the disease in the peripheral blood may need further studies to determine useful markers. In this study, we aimed to detect B cell associated factors concerning immunosuppressive treatment in generalized non-thymomatous MG patients. Although CD19(+) B cell distribution did not vary among disease subgroups, expressions of both CD38 and BAFFR were altered on B cells in MG patients under immunosuppressive therapy. Serum levels of BAFF were elevated in untreated MG patients as compared to treated MG patients and healthy controls. B cell activation factors may show profound alterations due to immunosuppression.
Files
bib-f47bb2f0-c2f2-4427-aef1-ec1ce0a7f21b.txt
Files
(273 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:5e9bebc6173fb0803102302c3ff4aad3
|
273 Bytes | Preview Download |